Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients

Antiviral Therapy

Volumn 15, Issue 1, 2010, Pages 51-59

  Maggiolo, Franco ^a   Roat, Erika ^b   Pinti, Marcello ^b   Nasi, Milena ^b   Gibellini, Lara ^b   De Biasi, Sara ^b   Airoldi, Monica ^a   Ravasio, Veronica ^a   Mussini, Cristina ^b   Suter, Fredy ^a   Cossarizza, Andrea ^b  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; MITOCHONDRIAL DNA; MITOCHONDRIAL RNA; TENOFOVIR DISOPROXIL; VIRUS DNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION RISK; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL TOXICITY; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS LOAD;

ADENINE; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; DIDANOSINE; DIDEOXYNUCLEOSIDES; DNA, MITOCHONDRIAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MITOCHONDRIA; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; RNA;

EID: 77949398882     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1483     Document Type: Article

References (50)

1. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22:685-708.
2. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354:1112-1115.
3. Cossarizza A, Moyle G. Antiretroviral nucleoside and nucleotide analogues and the mitochondria. AIDS 2004; 18:137-151.
4. Martin JL, Brown CE, Matthews-Davis N, Reardon JE. Effects of antiviral nucleoside analogs on human DNA polymerase and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994; 38:2743-2749.
5. Côté HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346:811-820.
6. McComsey G, Tan DJ, Lederman M, Wilson E, Wong LJ. Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy. AIDS 2002; 16:513-518.
7. Shiramizu B, Shikuma KM, Kamemoto L, et al. Placenta and cord blood mitochondrial DNA toxicity in HIVinfected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J Acquir Immune Defic Syndr 2003; 32:370-374.
8. Haugaard SB, Andersen O, Pedersen SB, et al. Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy. J Med Virol 2005; 77:29-38.
9. Setzer B, Schlesier M, Thomas AK, Walker UA. Mitochondrial toxicity of nucleoside analogues in primary human lymphocytes. Antivir Ther 2005; 10:327-334.
10. López S, Coll O, Durban M, et al. Mitochondrial DNA depletion in oocytes of HIV-infected antiretroviral-treated infertile women. Antivir Ther 2008; 13:833-838.
11. Cossarizza A. Tests for mitochondrial function and DNA: potentials and pitfalls. Curr Opin Infect Dis 2003; 16:5-10.
12. Mussini C, Pinti M, Bugarini R, et al. Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study. AIDS 2005; 19:1627-1633.
13. Banas B, Kost BP, Goebel FD. Platelets, a typical source of error in real-time PCR quantification of mitochondrial DNA content in human peripheral blood cells. Eur J Med Res 2004; 9:371-377.
14. Anderson PL, Kakuda TN, Lichtenstein KA. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis 2004; 38:743-753.
15. + children with HAART-related lipodystrophy. J Infect Dis 2002; 185:299-305.
16. Rosso R, Nasi M, Di Biagio A, et al. Effects of the change from stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function. Pediatr Infect Dis J 2008; 27:17-21.
17. Galluzzi L, Pinti M, Troiano L, et al. Changes in mitochondrial RNA production in cells treated with nucleoside analogues. Antivir Ther 2005; 10:191-195.
18. Galluzzi L, Pinti M, Guaraldi G, et al. Altered mitochondrial RNA production in adipocytes from HIV-infected individuals with lipodystrophy. Antivir Ther 2005; 10 Suppl 2:M91-M99.
19. Mallon PW, Unemori P, Sedwell R, et al. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 2005; 191:1686-1696.
20. Ferraresi R, Troiano L, Rossi D, et al. Mitochondrial membrane potential and nucleosidic inhibitors of HIV reverse transcriptase: a cytometric approach. Mitochondrion 2004; 4:271-278.
21. Caron M, Auclair M, Lagathu C, et al. The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS 2004; 18:2127-2136.
22. Ferraresi R, Troiano L, Roat E, et al. Protective effect of acetyl-l-carnitine against oxidative stress induced by antiretroviral drugs. FEBS Lett 2006; 580:6612-6616.
23. Salvioli S, Ardizzoni A, Franceschi C, Cossarizza A. JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett 1997; 411:77-82.
24. Troiano L, Ferraresi R, Lugli E, et al. Multiparametric analysis of cells with different mitochondrial membrane potential during apoptosis by polychromatic flow cytometry. Nat Protoc 2007; 2:2719-2727.
25. Cossarizza A, Baccarani-Contri M, Kalashnikova G, Franceschi C. A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5′,6,6′- tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem Biophys Res Commun 1993; 197:40-45.
26. Garcia Fernandez M, Troiano l, Moretti l, et al. Early changes in intramitochondrial cardiolipin distribution during apoptosis. Cell Growth Differ 2002; 13:449-455.
27. Torti C, Quiros-Roldan ME, Cologni G, et al. Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naive to antiretrovirals. Curr HIV Res 2008; 6:43-48.
28. Johnson AA, Ray AS, Hanes J, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001; 276:40847-40857.
29. Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16:2165-2173.
30. López S, Negredo E, Garrabou G, et al. Longitudinal study on mitochondrial effects of didanosine-tenofovir combination. AIDS Res Hum Retroviruses 2006; 22:33-39.
31. Levy RJ, Deutschman CS. Deficient mitochondrial biogenesis in critical illness: cause, effect, or epiphenomenon? Crit Care 2007; 11:158.
32. Reiss P, Casula M, de Ronde A, Weverling GJ, Goudsmit J, Lange JM. Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors. HIV Med 2004; 5:11-14.
33. Miura T, Goto M, Hosoya N, et al. Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy. J Med Virol 2003; 70:497-505.
34. Saitoh A, Fenton T, Alvero C, Fletcher CV, Spector SA. Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2007; 51:4236-4242.
35. Walker UA, Bickel M, Lutke Volksbeck SI, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 2002; 29:117-121.
36. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17:1329-1338.
37. Cherry CL, Gahan ME, McArthur JC, Lewin SR, Hoy JF, Wesselingh SL. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr 2002; 30:271-277.
38. Gerschenson M, Kim C, Berzins B, et al. Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. J Antimicrob Chemother 2009; 63:1244-1250.
39. Giordano C, Sebastiani M, Plazzi G, et al. Mitochondrial neurogastrointestinal encephalomyopathy: evidence of mitochondrial DNA depletion in the small intestine. Gastroenterology 2006; 130:893-901.
40. Sebastiani M, Giordano C, Nediani C, et al. Induction of mitochondrial biogenesis is a maladaptive mechanism in mitochondrial cardiomyopathies. J Am Coll Cardiol 2007; 50:1362-1369.
41. Zanna C, Ghelli A, Porcelli AM, et al. OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion. Brain 2008; 131:352-367.
42. Frisard MI, Broussard A, Davies SS, et al. Aging, resting metabolic rate, and oxidative damage: results from the Louisiana Healthy Aging Study. J Gerontol A Biol Sci Med Sci 2007; 62:752-759.
43. Dahmani Y, Marcuello A, Diez-Sanchez C, Ruiz-Pesini E, Montoya J, Lopez-Perez MJ. Association of human mitochondrial DNA variants with plasma LDL levels. Mitochondrion 2008; 8:247-253.
44. Lee HK, Song JH, Shin CS, et al. Decreased mitochondrial DNA content in peripheral blood precedes the development of non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1998; 42:161-167.
45. Park KS, Lee KU, Song JH, et al. Peripheral blood mitochondrial DNA content is inversely correlated with insulin secretion during hyperglycemic clamp studies in healthy young men. Diabetes Res Clin Pract 2001; 52:97-102.
46. Lim S, Park KS, Kim MS, Cho BY, Lee HK. Relationship between various surrogate indices of insulin resistance and mitochondrial DNA content in the peripheral blood of 18 healthy volunteers. Mitochondrion 2001; 1:71-77.
47. Lim S, Kim MS, Park KS, et al. Correlation of plasma homocysteine and mitochondrial DNA content in peripheral blood in healthy women. Atherosclerosis 2001; 158:399-405.
48. Stocco DM. StAR protein and the regulation of steroid hormone biosynthesis. Annu Rev Physiol 2001; 63:193-213.
49. Yao PM, Tabas I. Free cholesterol loading of macrophages is associated with widespread mitochondrial dysfunction and activation of the mitochondrial apoptosis pathway. J Biol Chem 2001; 276:42468-42476.
50. Cossarizza A, Riva A, Pinti M, et al. Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy. Antivir Ther 2003; 8:315-321.